AJANTA PHARMA LTD - Q4 FY 20 - RESULTS REVIEW

AJANTA PHARMA LTD

Q4 FY 20 RESULTS REVIEW

MANAGEMENT

  Name                           :     Designation

  Mannalal B Agrawal      :     Chairman

  Madhusudan B Agrawal :     Vice Chairman

  Yogesh M Agrawal        :     Managing Director

  Rajesh M Agrawal         :     Joint Managing Director

Ajanta Pharma Limited (APL), is engaged in manufacturing pharmaceutical products. 

The company runs three divisions -- prescription drugs, OTC and institutional sales. 

They cater to therapeutic areas like cardiology, ophthalmology and dermatology.

They manufacture various dosage forms such as tablets, capsules, injections, ointments and powders. 

The company’s research and development division conduct activities in three aspects namely new drug delivery system (NDDS), formulation and development and herbal/ nutraceutical.

Ajanta Pharma (in Rs. Cr.)	Mar '20	Dec '19	Sep '19	Jun '19	Mar '19	YOY	QOQ
Net Sales	681.96	651.21	642.76	611.94	515.16	32.38	4.72
Consumption of Raw Materials	173.53	138.34	124.28	124.18	126.82	36.83	25.44
Purchase of Traded Goods	29.69	24.15	24.54	33.75	11.65	154.85	22.94
Increase/Decrease in Stocks	-25.62	6.6	17.66	-15.39	-32.94	-22.22	-488.18
Employees Cost	129.48	120.38	117.41	118.32	107.4	20.56	7.56
Depreciation	26.04	23.6	23.3	22.78	18.75	38.88	10.34
Other Expenses	223.54	175.77	181.23	182.7	175.15	27.63	27.18
P/L Before Other Inc., Int., Excpt. Items & Tax	125.3	162.37	154.34	145.6	108.33	15.67	-22.83
Other Income	56.69	14.64	13.22	7.64	1.63	3377.91	287.23
P/L Before Int., Excpt. Items & Tax	181.99	177.01	167.56	153.24	109.96	65.51	2.81
Interest	3.62	1.57	4.93	1.79	0.77	370.13	130.57
P/L Before Exceptional Items & Tax	178.37	175.44	162.63	151.45	109.19	63.36	1.67
Exceptional Items	-2.51	-0.34	-1.07	--	--		638.24
P/L Before Tax	175.86	175.1	161.56	151.45	109.19	61.06	0.43
Tax	46.7	67.55	45.2	36.82	20.3	130.05	-30.87
N P T	129.16	107.55	116.36	114.63	88.89	45.3	20.09
Equity Share Capital	17.54	17.54	17.54	17.54	17.54	0	0
Basic EPS	14.8	12.33	13.34	13.14	10.1	46.53	20.03
Diluted EPS	14.8	12.32	13.33	13.14	10.1	46.53	20.13
MP	NSE Live	Ju 23, 15:59		1462.70 8.95 (0.62%)
PE	24.71
Volume	76,852
52 W L H	840	1578.1
Valuation
Market Cap (Rs Cr.)		12,736.22
P/E		28.94
Book Value (Rs)		282.05
Dividend (%)		650
Industry P/E		31.4
EPS (TTM)		50.55
Price/Book		5.17
Dividend Yield.(%)		0.89
Face Value (RS)		2
Deliverables (%)		39.05
Share Holding Pattern in (%)
Standalone	Mar-20	Dec-19	Sep-19	Jun-19
Promoters	70.51	70.51	70.51	70.52
Pledged	17.29	16.86	17.77	13.37
FII/FPI	8.91	7.9	7.68	9.45
Total DII	12.54	13.2	13.44	11.63
Fin.Insts	0.17	0.18	0.17	0.39
Insurance Co	0.45	0.47	0.28	0
MF	9.25	10.37	10.79	9.09
Others DIIs	2.67	2.18	2.2	2.15
Others	8.04	8.39	8.35	8.4
Total	100	100	99.98	100

In March 2019, the Company bought back 7,69,230 (Seven lakhs sixty-nine thousand two hundred and thirty only) fully paid-up equity shares of the face value of Rs. 2/- each, representing 0.87% of the total number of equity shares

6% of Revenue is being spent on R&D (Rs.164 CR)

150+ Products

30+ countries

7000+ Ajanta Team

INVESTOR PRESENTATION

Q4 FY 2020

20thMay 2020

15 Divisions for 4 segments

3,000+MRs Building Efficiency

270+ Product Basket

1^st to Market Products

Cardiology : Efforts are on to increase the growth rate; Grows at 11%

Ophthalmology : rate2ndlargest in India& still growing above the segment ; Grows at 17%

Dermatology : Growth Revives ; Grows at 6%

Pain Management  :  Gained 2 ranks ; Grows at 16%

By March 2020, Ajanta has grown 13 % as against 11% of the Industry

Enabling Infrastructure

Formulation Manufacturing

3 facilities in Aurangabad, Maharashtra1 facility at Dahej, Gujarat 

1 facility at Guwahati, Assam, Ophthalmic bloc to commence operation in Q2 FY21

New facility operationalized at Pithampur, Madhya Pradesh

1 facility at Mauritius

API Manufacturing

1 Facility at Waluj, Aurangabad, Maharashtra (Captive Consumption)